{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:07:31Z","timestamp":1779365251089,"version":"3.53.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Migraine is a common and disabling neurological disorder in children, often requiring preventive treatment. This study aimed to compare the efficacy and tolerability of cinnarizine and topiramate in the prophylaxis of migraine in children and adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In this randomized, double-blind, parallel-group clinical trial, 96 children aged 6\u201315 years with a diagnosis of migraine according to the International Classification of Headache Disorders (ICHD-3) [1], including both migraine with and without aura, without restriction to specific subtypes were enrolled. Participants were randomly assigned to receive either cinnarizine (25\u00a0mg once daily) or topiramate (25\u00a0mg once daily) for 12 weeks. Migraine attack frequency and severity were recorded using headache diaries at baseline, one month, and three months after treatment initiation. The primary outcome was the change in monthly migraine attack frequency. Secondary outcomes included changes in headache severity and the occurrence of adverse events. Between-group comparisons were performed using the Mann\u2013Whitney U test, and within-group changes over time were analyzed using the Friedman test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both cinnarizine and topiramate significantly reduced monthly migraine attack frequency and headache severity over the 12-week treatment period (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001 for within-group comparisons). At three months, the median number of migraine attacks decreased to two attacks per month in both groups, with no statistically significant difference observed between the two treatments (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.81). Headache severity scores also improved significantly in both groups, and no between-group differences were observed at follow-up (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.74). Both medications were generally well tolerated, with no statistically significant differences in the incidence of adverse events between groups. Appetite reduction was reported in 4.2% of the cinnarizine group versus 14.6% of the topiramate group. While a numerically lower incidence of appetite reduction was observed in the cinnarizine group (4.2% vs. 14.6%), this difference was not statistically significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.159, Fisher\u2019s exact test; OR\u2009=\u20090.255, 95% CI: 0.05\u20131.27).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both cinnarizine and topiramate significantly reduced the frequency and severity of migraine attacks in children. No statistically significant difference in efficacy was detected between the two treatments. A numerically lower incidence of appetite reduction was observed with cinnarizine, although this difference was not statistically significant. Larger studies are needed to evaluate potential differences in tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Iranian Registry of Clinical Trials (IRCT) IRCT20221108056444N1. Registered 12 February 2023 Retrospectively registered,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.en.irct.ir\/trial\/66774\" ext-link-type=\"uri\">https:\/\/www.en.irct.ir\/trial\/66774<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-04950-1","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:24:37Z","timestamp":1778300677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cinnarizine vs. topiramate for migraine prophylaxis in children: a randomized, double-blind, parallel-group clinical trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-2290","authenticated-orcid":false,"given":"Alireza","family":"Abdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-2911","authenticated-orcid":false,"given":"Ezatollah","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8945-1638","authenticated-orcid":false,"given":"Aisan","family":"Abazarlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"4950_CR1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"9","key":"4950_CR2","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML, Schwedt TJ, Dodick DW. Migraine in America Symptoms and Treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache: J Head Face Pain. 2018;58(9):1408\u201326.","journal-title":"Headache: J Head Face Pain"},{"key":"4950_CR3","doi-asserted-by":"crossref","unstructured":"Ailani J, Burch RC, Robbins MS, Society B. o. D. o. t. A. H. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache: J Head Face Pain. 2021;61(7);1021\u20131039.","DOI":"10.1111\/head.14153"},{"key":"4950_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40272-015-0125-5","volume":"17","author":"J Kacperski","year":"2015","unstructured":"Kacperski J. Prophylaxis of migraine in children and adolescents. Pediatr Drugs. 2015;17:217\u201326.","journal-title":"Pediatr Drugs"},{"issue":"1","key":"4950_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s10194-023-01541-0","volume":"24","author":"A Onofri","year":"2023","unstructured":"Onofri A, Pensato U, Rosignoli C, Wells-Gatnik W, Stanyer E, Ornello R, Chen HZ, De Santis F, Torrente A, Mikulenka P. Primary headache epidemiology in children and adolescents: a systematic review and meta-analysis. J Headache Pain. 2023;24(1):8.","journal-title":"J Headache Pain"},{"key":"4950_CR6","doi-asserted-by":"publisher","unstructured":"Lu G, Xiao S, Wang Y, Jia Q, Liu S, Yu S, Liu R, Yang W. Global epidemiology and burden of headache disorders in children and adolescents from 1990 to 2021. Headache. 2025;65(7):1170\u201379. https:\/\/doi.org\/10.1111\/head.14937.","DOI":"10.1111\/head.14937"},{"issue":"1","key":"4950_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12883-023-03215-5","volume":"23","author":"P Mohammadi","year":"2023","unstructured":"Mohammadi P, Khodamorovati M, Vafaee K, Hemmati M, Darvishi N, Ghasemi H. Prevalence of migraine in Iran: a systematic review and meta-analysis. BMC Neurol. 2023;23(1):172.","journal-title":"BMC Neurol"},{"issue":"2","key":"4950_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/1817-1745.92818","volume":"6","author":"H Fallahzadeh","year":"2011","unstructured":"Fallahzadeh H, Alihaydari M. Prevalence of migraine and tension-type headache among school children in Yazd, Iran. J Pediatr Neurosciences. 2011;6(2):106\u20139.","journal-title":"J Pediatr Neurosciences"},{"issue":"12","key":"4950_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1136\/archdischild-2021-322373","volume":"107","author":"NR Loh","year":"2022","unstructured":"Loh NR, Whitehouse WP, Howells R. What is new in migraine management in children and young people? Arch Dis Child. 2022;107(12):1067\u201372.","journal-title":"Arch Dis Child"},{"issue":"10","key":"4950_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11916-023-01157-8","volume":"27","author":"RG Rastogi","year":"2023","unstructured":"Rastogi RG, Hastriter EV, Evans RL, Bassal F, Hickman C, Karnik KT, Little R, Lewis KS. Advances in the acute and preventive treatment of pediatric migraine. Curr Pain Headache Rep. 2023;27(10):521\u20139.","journal-title":"Curr Pain Headache Rep"},{"issue":"3","key":"4950_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/medicina61030450","volume":"61","author":"A Almaqhawi","year":"2025","unstructured":"Almaqhawi A, Alokley A, Alamri R, Alabdulqader R, Alali A, Aleid A, Alhejji A, ALNasser MN. Effectiveness of Topiramate Versus Acetazolamide in the Management of Idiopathic Intracranial Hypertension: ASystematic Review and Meta-Analysis. Medicina. 2025;61(3):450.","journal-title":"Medicina"},{"issue":"2","key":"4950_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/0333102418776455","volume":"39","author":"WJ Scotton","year":"2019","unstructured":"Scotton WJ, Botfield HF, Westgate CS, Mitchell JL, Yiangou A, Uldall MS, Jensen RH, Sinclair AJ. Topiramate is more effective than acetazolamide at lowering intracranial pressure. Cephalalgia. 2019;39(2):209\u201318.","journal-title":"Cephalalgia"},{"issue":"10","key":"4950_CR13","doi-asserted-by":"publisher","first-page":"e2438666","DOI":"10.1001\/jamanetworkopen.2024.38666","volume":"7","author":"OK Gargari","year":"2024","unstructured":"Gargari OK, Aghajanian S, Togha M, Mohammadifard F, Abyaneh R, Sani SM, Samiee R, Kermanpour A, Seighali N, Haghdoost F. Preventive Medications in Pediatric Migraine: A Network Meta-Analysis. JAMA Netw Open. 2024;7(10):e2438666\u20132438666.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"4950_CR14","doi-asserted-by":"publisher","first-page":"033310242412309","DOI":"10.1177\/03331024241230963","volume":"44","author":"M Olfat","year":"2024","unstructured":"Olfat M, Hosseinpour S, Masoumi S, Gogia Rastogi R, Vance Hastriter E, Lewis KS, Little R, Karnik T, Hickman K, C., Heidari M. A comparative study on prophylactic efficacy of cinnarizine and amitriptyline in childhood migraine: a randomized double-blind clinical trial. Cephalalgia. 2024;44(4):03331024241230963.","journal-title":"Cephalalgia"},{"issue":"10","key":"4950_CR15","doi-asserted-by":"publisher","first-page":"e2290","DOI":"10.1002\/brb3.2290","volume":"11","author":"C Hu","year":"2021","unstructured":"Hu C, Zhang Y, Tan G. Advances in topiramate as prophylactic treatment for migraine. Brain Behav. 2021;11(10):e2290.","journal-title":"Brain Behav"},{"issue":"4","key":"4950_CR16","first-page":"18","volume":"8","author":"MR Ashrafi","year":"2014","unstructured":"Ashrafi MR, Najafi Z, Shafiei M, Heidari K, Togha M. Cinnarizine versus topiramate in prophylaxis of migraines among children and adolescents: a randomized, double-blind clinical trial. Iran J child Neurol. 2014;8(4):18.","journal-title":"Iran J child Neurol"},{"key":"4950_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s13760-012-0011-7","volume":"112","author":"M Togha","year":"2012","unstructured":"Togha M, Malamiri RA, Rashidi-Ranjbar N, Asa S, Mahvelati F, Ashrafi MR. Efficacy and safety of cinnarizine in the prophylaxis of migraine headaches in children: an open, randomized comparative trial with propranolol. Acta Neurol Belgica. 2012;112:51\u20135.","journal-title":"Acta Neurol Belgica"},{"issue":"7","key":"4950_CR18","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.21037\/tp-20-478","volume":"10","author":"G Jia","year":"2021","unstructured":"Jia G, Wang X, Lv H, Nonyane MSC, Hou H, Ma L, Shan P, Wu X. The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials. Translational Pediatr. 2021;10(7):1779.","journal-title":"Translational Pediatr"},{"issue":"8","key":"4950_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/papr.13164","volume":"22","author":"M Shafie\u2019ei","year":"2022","unstructured":"Shafie\u2019ei M, Kouhanjani MF, Akbari Z, Sarvipour N, Shekouh D, Gholampour M, Ardestani PM, Nemati H. Application of cinnarizine in migraine prevention: A systematic review and meta-analysis. Pain Pract. 2022;22(8):733\u201345.","journal-title":"Pain Pract"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04950-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04950-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04950-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:30:08Z","timestamp":1779363008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04950-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4950"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04950-1","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Urmia University of Medical Sciences (IR.UMSU.REC.1401.277) and registered in the Iranian Clinical Trials Registry (IRCT20221108056444N1; registered on 2023-02-12- Retrospectively registered). All participants or their legal guardians provided written informed consent following the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"348"}}